Patents by Inventor Ying-Ju Sung
Ying-Ju Sung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10485845Abstract: The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.Type: GrantFiled: July 30, 2015Date of Patent: November 26, 2019Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Richard Ambron, Ying-Ju Sung, Donald W. Landry, Shi-Xian Deng
-
Patent number: 10016468Abstract: The subject invention pertains to probiotic compositions and methods of treating hepatocellular carcinoma (HCC) using the probiotic compositions. The probiotic compositions can inhibit growth of HCC. The probiotic compositions can reduce the risk of HCC. The probiotic compositions include a specific combination of three bacterial compositions: (a) heat-inactivated Lactobacillus rhamnosus GG deposited under accession number ATCC 53103, also known as, Lactobacillus acidophilus (Moro) Hansen and Macquot, (b) viable Escherichia coli Nissle 1917, and (c) heat-inactivated VSL#3®. This combination of bacteria is effective to reduce hepatocellular carcinoma (HCC) growth compared to control growth.Type: GrantFiled: August 15, 2014Date of Patent: July 10, 2018Assignee: VERSITECH LIMITEDInventors: Hani El-Nezamy, Nikki Pui-Yue Lee, Cecilia Ying Ju Sung, Jiandong Huang
-
Patent number: 9402826Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.Type: GrantFiled: September 29, 2014Date of Patent: August 2, 2016Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
-
Publication number: 20150320761Abstract: The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.Type: ApplicationFiled: July 30, 2015Publication date: November 12, 2015Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventors: Richard Ambron, Ying-Ju Sung, Donald W. Landry, Shi-Xian Deng
-
Patent number: 9107868Abstract: The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.Type: GrantFiled: August 8, 2012Date of Patent: August 18, 2015Assignee: The Trustees of Columbia University in the City of New YorkInventors: Richard Ambron, Ying-Ju Sung, Donald W. Landry, Shi-Xian Deng
-
Publication number: 20150164964Abstract: The subject invention pertains to probiotic compositions and methods of treating hepatocellular carcinoma (HCC) using the probiotic compositions. The probiotic compositions can inhibit growth of HCC. The probiotic compositions can reduce the risk of HCC. The probiotic compositions include a specific combination of three bacterial compositions: (a) heat-inactivated Lactobacillus acidophilus (Moro) Hansen and Mocqu (ATCC 53103), (b) viable Escherichia coli Nissle 1917, and (c) heat-inactivated VSL#3®. This combination of bacteria is effective to reduce hepatocellular carcinoma (HCC) growth compared to control growth.Type: ApplicationFiled: August 15, 2014Publication date: June 18, 2015Inventors: Hani El-Nezamy, Nikki Pui-Yue Lee, Cecilia Ying Ju Sung, Jiandong Huang
-
Publication number: 20150126576Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.Type: ApplicationFiled: September 29, 2014Publication date: May 7, 2015Applicant: The Trustees of Columbia University in the City of New YorkInventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
-
Patent number: 8846742Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.Type: GrantFiled: February 14, 2007Date of Patent: September 30, 2014Assignee: The Trustees of Columbia University in the City of New YorkInventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
-
Publication number: 20120295853Abstract: The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.Type: ApplicationFiled: August 8, 2012Publication date: November 22, 2012Inventors: Richard Ambron, Ying-Ju Sung, Donald W. Landry, Shi-Xian Deng
-
Patent number: 8252754Abstract: The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.Type: GrantFiled: March 21, 2006Date of Patent: August 28, 2012Assignee: The Trustees of Columbia University in the City of New YorkInventors: Richard Ambron, Ying-Ju Sung, Donald W. Landry, Shi-Xian Deng
-
Publication number: 20080176920Abstract: The present invention relates to compounds that may be used to inhibit activation of protein kinase G (“PKG”). It is based, at least in part, on the discovery of the tertiary structure of PKG and the identification of molecules that either bind to the active site of PKG and/or are analogs of balanol.Type: ApplicationFiled: February 14, 2007Publication date: July 24, 2008Inventors: Richard Ambron, Ying-Ju Sung, Jeremy Greenwood, Leah Frye, Shi-Xian Deng, Yuli Xie, Donald W. Landry
-
Publication number: 20060216339Abstract: The present invention relates to the discovery of a novel molecular pathway involved in long-term hyperexcitability of sensory neurons, which, in higher animals, is associated with persistent pain. It is based on the discovery that, following injury to an axon of a neuron, an increase in nitric oxide synthase activity results in increased nitric oxide production, which, in turn, activates guanylyl cyclase, thereby increasing levels of cGMP. Increased cGMP results in activation of protein kinase G (“PKG”), which then is retrogradely transported along the axon to the neuron cell body, where it phosphorylates MAPKerk.Type: ApplicationFiled: March 21, 2006Publication date: September 28, 2006Inventors: Richard Ambron, Ying-Ju Sung, Donald Landry, Shi-Xian Deng